Femoral Artery Occlusion, Femoral Artery Stenosis, Popliteal Artery Occlusion, Popliteal Artery Stenosis
Conditions
Keywords
Legs, Drug Coated Angioplasty Balloon, Experimental, Standard Angioplasty Balloon
Brief summary
The post approval study will enroll US female patients presenting with claudication or ischemic rest pain and an angiographically significant lesion in the superficial femoral or popliteal artery. Subjects are treated per Instructions For Use (IFU) with the Lutonix® Catheter. Subjects will have a Duplex Ultrasound (DUS) and clinical follow-up through two (2) years.
Detailed description
The Lutonix® 035 Drug Coated Balloon PTA Catheter (Lutonix® Catheter) has been approved by the Food and Drug Administration (P130024) for percutaneous transluminal angioplasty, after appropriate vessel preparation of de novo, restenotic, or in-stent restenotic lesions up to 300 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-7 mm. The purpose of this post-approval study is to assess the safety and effectiveness of the Lutonix® Catheter in the US female population. This study will enroll approximately 165 female patients at a minimum of 10 US centers and a maximum of 25.
Interventions
DEVICELutonix® 035 Drug Coated Balloon PTA Catheter
Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Sponsors
C. R. Bard
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Clinical Criteria 1. Non-pregnant female ≥18 years of age; 2. Rutherford Clinical Category 2-4; 3. Patient is willing to provide informed consent, is geographically stable, comply with the required follow up visits and testing schedule; Angiographic Criteria 4. De novo or restenotic lesion(s) in native superficial femoral or popliteal arteries; 5. Lesion ≥70% stenosis by visual estimate; 6. Target reference vessel diameter of 4-7 mm; 7. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography; (Treatment of target lesion acceptable after successful treatment of inflow artery lesions. Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication.) 8. At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography after successful vessel preparation; 9. Successful antegrade wire crossing and vessel preparation (may include pre-dilatation) of the target lesion. Successful vessel preparation is defined by residual stenosis ≤30% without any major vascular complications; 10. No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment except for remote common femoral patch angioplasty separated by at least 2 cm from the lesion(s).
Exclusion criteria
1. Life expectancy of \<2 years; 2. Subject is currently participating in an investigational drug or device study, or previously enrolled in this study. Enrollment in another investigational drug or device study during the follow up period is not allowed; 3. History of stroke within 3 months; 4. History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of index procedure; 5. Renal failure or chronic kidney disease with serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis; 6. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure | 12 months post index procedure | Index limb amputation includes above or below the ankle amputations. |
| Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure. | 12 months post index procedure | Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis. |
Secondary
| Measure | Time frame |
|---|---|
| Number of Deaths (All Causes) at 30 Days Post Index Procedure | 30 days post index procedure |
| Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure | 1, 6, 12 and 24 months post index procedure |
| Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure | 1, 6, 12 and 24 months post index procedure |
| Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure | 1, 6, 12 and 24 months post index procedure |
| Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death. | 30 days post index procedure |
| Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure. | 1, 6, 12 and 24 months |
| Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline | 1, 6, 12 and 24 months post index procedure |
| Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure | 1, 6, 12 and 24 months post index procedure |
| Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline | 1, 6, 12 and 24 months post index procedure |
| Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure | 1, 6, 12 and 24 months post index procedure |
| Number of Major Vascular Complications at 30 Days Post Index Procedure | 30 days |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lutonix® 035 Drug Coated Balloon PTA Catheter This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.
Lutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter. | 4 |
| Total | 4 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Study terminated | 4 |
Baseline characteristics
| Characteristic | Lutonix® 035 Drug Coated Balloon PTA Catheter |
|---|---|
| Age, Customized ≥18 years of age | 4 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 3 Participants |
| Region of Enrollment United States | 4 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 4 |
| other Total, other adverse events | 0 / 4 |
| serious Total, serious adverse events | 0 / 4 |
Outcome results
Primary
Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.
Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.
Time frame: 12 months post index procedure
Population: Study was terminated.
Primary
Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure
Index limb amputation includes above or below the ankle amputations.
Time frame: 12 months post index procedure
Population: Study was terminated.
Secondary
Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline
Time frame: 1, 6, 12 and 24 months post index procedure
Population: Study was terminated.
Secondary
Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline
Time frame: 1, 6, 12 and 24 months post index procedure
Population: Study was terminated.
Secondary
Number of Deaths (All Causes) at 30 Days Post Index Procedure
Time frame: 30 days post index procedure
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lutonix® 035 Drug Coated Balloon PTA Catheter | Number of Deaths (All Causes) at 30 Days Post Index Procedure | 0 Participants |
Secondary
Number of Major Vascular Complications at 30 Days Post Index Procedure
Time frame: 30 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lutonix® 035 Drug Coated Balloon PTA Catheter | Number of Major Vascular Complications at 30 Days Post Index Procedure | 0 Complications |
Secondary
Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.
Time frame: 1, 6, 12 and 24 months
Population: Study was terminated.
Secondary
Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Population: Study terminated.
Secondary
Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.
Time frame: 30 days post index procedure
Population: Study was terminated.
Secondary
Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Population: Study was terminated.
Secondary
Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Population: Study was terminated.
Secondary
Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure
Time frame: 1, 6, 12 and 24 months post index procedure
Population: Study was terminated.
Secondary
Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure
Time frame: 1, 6, 12 and 24 months post index procedure
Population: Study was terminated.